191 related articles for article (PubMed ID: 18703593)
1. 131I effective half-life and dosimetry in thyroid cancer patients.
Remy H; Borget I; Leboulleux S; Guilabert N; Lavielle F; Garsi J; Bournaud C; Gupta S; Schlumberger M; Ricard M
J Nucl Med; 2008 Sep; 49(9):1445-50. PubMed ID: 18703593
[TBL] [Abstract][Full Text] [Related]
2. 131I effective half-life (Teff) for patients with thyroid cancer.
Willegaignon J; Malvestiti LF; Guimarães MI; Sapienza MT; Endo IS; Neto GC; Marone M; Sordi GM
Health Phys; 2006 Aug; 91(2):119-22. PubMed ID: 16832192
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer therapy.
Willegaignon J; Stabin MG; Guimarães MI; Malvestiti LF; Sapienza MT; Maroni M; Sordi GM
Health Phys; 2006 Aug; 91(2):123-7. PubMed ID: 16832193
[TBL] [Abstract][Full Text] [Related]
5. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
6. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma.
Dauer LT; St Germain J; Williamson MJ; Zanzonico P; Modak S; Cheung NK; Divgi C
Health Phys; 2007 Jan; 92(1):33-9. PubMed ID: 17164597
[TBL] [Abstract][Full Text] [Related]
7. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.
Menzel C; Kranert WT; Döbert N; Diehl M; Fietz T; Hamscho N; Berner U; Grünwald F
J Nucl Med; 2003 Jul; 44(7):1065-8. PubMed ID: 12843221
[TBL] [Abstract][Full Text] [Related]
8. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.
Hänscheid H; Lassmann M; Luster M; Kloos RT; Reiners C
Endocr Relat Cancer; 2009 Dec; 16(4):1283-9. PubMed ID: 19628649
[TBL] [Abstract][Full Text] [Related]
9. 131I Biokinetics and cytogenetic dose estimates in ablation treatment of thyroid carcinoma.
Nascimento AC; Lipsztein JL; Corbo R; Rebelo AM
Health Phys; 2010 Oct; 99(4):457-63. PubMed ID: 20838086
[TBL] [Abstract][Full Text] [Related]
10. Coming of age: recombinant human thyroid-stimulating hormone as a preparation for (131)i therapy in thyroid cancer.
Robbins RJ; Pentlow KS
J Nucl Med; 2003 Jul; 44(7):1069-71. PubMed ID: 12843222
[No Abstract] [Full Text] [Related]
11. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters.
Huysmans DA; Buijs WC; van de Ven MT; van den Broek WJ; Kloppenborg PW; Hermus AR; Corstens FH
J Nucl Med; 1996 Dec; 37(12):2072-9. PubMed ID: 8970537
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
[TBL] [Abstract][Full Text] [Related]
13. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
[TBL] [Abstract][Full Text] [Related]
14. 1-11C-methyl-4-piperidinyl-N-butyrate radiation dosimetry in humans by dynamic organ-specific evaluation.
Virta JR; Tolvanen T; Någren K; Brück A; Roivainen A; Rinne JO
J Nucl Med; 2008 Mar; 49(3):347-53. PubMed ID: 18287260
[TBL] [Abstract][Full Text] [Related]
15. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
16. Correlation between external exposure and activity in patients undergoing 131I thyroid cancer therapy.
Barquero R; Basurto F; Vega-Carrillo HR; Iñiguez MP; Ferrer N; Esteban R
Health Phys; 2008 Aug; 95(2):227-33. PubMed ID: 18617804
[TBL] [Abstract][Full Text] [Related]
17. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
Breitz HB; Wendt RE; Stabin MS; Shen S; Erwin WD; Rajendran JG; Eary JF; Durack L; Delpassand E; Martin W; Meredith RF
J Nucl Med; 2006 Mar; 47(3):534-42. PubMed ID: 16513624
[TBL] [Abstract][Full Text] [Related]
18. [Radiobiologic basis for using 131I to treat patients with thyroid cancer].
Suwiński R; Gawkowska-Suwińska M
Wiad Lek; 2001; 54 Suppl 1():266-77. PubMed ID: 12182035
[TBL] [Abstract][Full Text] [Related]
19. [The effective half-life of 131I during the treatment of autonomous thyroid disease with radioiodine].
Müller B; Bares R; Büll U
Nuklearmedizin; 1991 Jun; 30(3):71-6. PubMed ID: 1714566
[TBL] [Abstract][Full Text] [Related]
20. Iodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease: clinical implications.
Courbon F; Caselles O; Zerdoud S; Duthil P; Regis H; Berry I; Caron P
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):363-70. PubMed ID: 17043635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]